Progression-free survival (PFS, A) and overall survival (OS, B) of low and other than low (low-intermediate, high-intermediate, and high) risk patients by IPI treated either with (N=32 and N=13) or without (N=18 and N=13) rituximab. IPI was not available in 4 patients in the no rituximab treatment group. These patients were excluded from the survival analyses. Median PFS and OS not reached.